Jeha Sima, Behm Frederick, Pei Deqing, Sandlund John T, Ribeiro Raul C, Razzouk Bassem I, Rubnitz Jeffrey E, Hijiya Nobuko, Howard Scott C, Cheng Cheng, Pui Ching-Hon
Department of Hematology-Oncology, St Jude Children's Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA.
Blood. 2006 Nov 15;108(10):3302-4. doi: 10.1182/blood-2006-04-016709. Epub 2006 Aug 8.
CD20 expression is associated with inferior survival in adults with acute lymphoblastic leukemia (ALL). We analyzed the prognostic impact of CD20 expression in 353 children with B-cell precursor ALL treated in 3 consecutive St Jude Total Therapy studies. CD20 expression (> 20%) was found in 169 patients (48%) and was more frequent in patients between 1 and 10 years of age than in those younger than 1 or older than 10 years (P = .001). None of 14 patients with MLL-AF4 expressed CD20. There was no association between CD20 expression and E2A-PBX, TEL-AML1, ploidy, white blood cell count at diagnosis, or sex. In contrast to the experience in adult ALL, our patients with CD20 expression tended to have a better treatment outcome than those without the expression: 5-year event-free survival 84% +/- 2.9% versus 78% +/- 3.1% (P = .08). These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens.
CD20表达与成人急性淋巴细胞白血病（ALL）的较差生存率相关。我们在连续3项圣裘德全疗法研究中分析了353例B细胞前体ALL儿童患者中CD20表达的预后影响。169例患者（48%）检测到CD20表达（>20%），1至10岁患者中的表达比小于1岁或大于10岁患者更常见（P = 0.001）。14例MLL-AF4患者均未表达CD20。CD20表达与E2A-PBX、TEL-AML1、倍性、诊断时白细胞计数或性别之间无关联。与成人ALL的情况相反，我们的CD20表达患者的治疗结局往往比未表达者更好：5年无事件生存率分别为84%±2.9%和78%±3.1%（P = 0.08）。这些数据表明，在接受当代治疗方案的儿科患者中，CD20表达与较差结局无关。
